Author

Scott D. Lee 1

1 University of Washington Medical Center,Seattle

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A SELECTIVE, ORAL SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD (APD334), IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE OASIS STUDY

William Sandborn, Laurent Peyrin-Biroulet, Luba Trokan, Jinkun Zhang, Tanja Kühbacher, Michael Chiorean, Scott D. Lee, Severine Vermeire, Bruce Yacyshyn, Snehal U. Naik, Preston Klassen, Julian Panés

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB

Marla C. Dubinsky, Remo Panaccione, James D Lewis, Bruce E. Sands, Toshifumi Hibi, Scott D. Lee, April Naegeli, Mingyang Shan, Linden Green, Nathan Morris, Vipin Arora, Alison Potts Bleakman, Ruth Belin, Simon Travis

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Marla C. Dubinsky, Scott D. Lee, Remo Panaccione, Maria T. Abreu, Severine Vermeire, Trevor Lissoos, Nathan Morris, Vipin Arora, Mingyang Shan, April Naegeli, Bruce E. Sands

ANDECALIXIMAB (ANTI-MMP9) INDUCTION THERAPY FOR CROHN’S DISEASE: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDY

Stefan Schreiber, Corey A Siegel, Keith Friedenberg, Ursula Seidler, Bal R. Bhandari, Ziad Younes, KE WANG, Matthew McKevitt, Sally Zhao, Bittoo Kanwar, John Sundy, Scott D. Lee, Edward V Loftus Jr

IMPROVED PATIENT-REPORTED OUTCOMES WITH UPADACITINIB AS AN INDUCTION THERAPY FOR PATIENTS WITH ULCERATIVE COLITIS: DATA FROM U-ACHIEVE

Subrata Ghosh, Jean-Frederic Colombel, Severine Vermeire, Scott D. Lee, Wan-Ju Lee, Wen Zhou, Fabio Cataldi, Ana P. Lacerda, Silvio Danese

INDUCTION THERAPY OF UPADACITINIB IS ASSOCIATED WITH IMPROVED SYMPTOMS IN BOWEL URGENCY AND ABDOMINAL PAIN FOR PATIENTS WITH ULCERATIVE COLITIS: DATA FROM U-ACHIEVE

Subrata Ghosh, Edouard Louis, Scott D. Lee, Fabio Cataldi, Bidan Huang, Wan-Ju Lee, Edward V. Loftus Jr

LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MADCAM-1 MONOCLONCAL ANTIBODY SHP647 IN CROHN'S DISEASE: THE OPERA II STUDY

Geert R. D'Haens, Walter Reinisch, Scott D. Lee, Dino Tarabar, Edouard Louis, Maria Kłopocka, Jochen G. Klaus, Stefan Schreiber, Dong Il Park, Xavier Hebuterne, Fabio Cataldi, Steven W Martin, Satyaprakash Nayak, Anindita Banerjee, Kenneth Gorelick, William Sandborn

PTG-100, AN ORAL GUT-RESTRICTED PEPTIDE α4β7 ANTAGONIST, INDUCES CLINICAL AND HISTOLOGIC REMISSION IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE ULCERATIVE COLITIS

William Sandborn, Brian Bressler, Scott D. Lee, Raj Bhandari, Bittoo Kanwar, Lucio Tozzi, Richard Shames, Geert R. D'Haens, Jean-Frederic Colombel, Stefan Schreiber, Silvio Danese, Rish K. Pai, Brian G. Feagan

RESPONSE AND REMISSION AFTER 16 WEEKS OF USTEKINUMAB– AN ALL PATIENTS ANALYSIS FROM THE UNITI CROHN’S STUDIES

Jean-Frederic Colombel, Sheldon Sloan, Christopher Gasink, Long-Long Gao, Douglas Jacobstein, Scott D. Lee, Stephan Targan

USTEKINUMAB IV INDUCTION RESULTS IN CROHN’S DISEASE SYMPTOM IMPROVEMENT WITHIN THE FIRST WEEK IN ANTI-TNF REFRACTORY PATIENTS    

William Sandborn, Benjamin Yeager, Christopher Gasink, Timothy Hoops, Long-Long Gao, Yanli Wang, Douglas Jacobstein, Scott D. Lee, Stephen B Hanauer

Item 1 - 10 / 10
1